Daniel Friedman

Dr. Daniel Friedman is an Assistant Professor in the Department of Medicine-Infectious Diseases at the University of Chicago. His clinical and research focus centers on managing infectious diseases in immunocompromised patients, particularly those undergoing solid organ or stem cell transplants, cancer treatments, or other high-risk conditions. He specializes in pre-transplant infection risk assessment, personalized preventive strategies, and invasive fungal infections in transplant recipients. His research also explores novel antifungal therapies and the epidemiology of infections in immunosuppressed populations.

Dr. Friedman has been actively involved in clinical trials for emerging antifungal treatments and diagnostic methods. His work bridges translational research and clinical care, with a strong emphasis on improving outcomes for high-risk patients. Notable collaborations include studies on risk factors for invasive aspergillosis in kidney transplant recipients and the impact of non-tuberculous mycobacteria on lung transplant outcomes.

His publications span topics such as fungal diagnostics, antifungal drug efficacy, and infection management in transplant recipients. He has co-authored studies on Pneumocystis jirovecii pneumonia in renal transplant patients and SARS-CoV-2 considerations in liver transplantation. His research networks include collaborations with institutions like the Mayo Clinic and the University of Alberta, focusing on infectious disease epidemiology and clinical trials.